(Q50684421)
Statements
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. (English)
1 reference
S V Sorensen
1 reference
A R Kansal
1 reference
S Connolly
1 reference
S Peng
1 reference
J Linnehan
1 reference
C Bradley-Kennedy
1 reference
J M Plumb
1 reference
22 March 2011
1 reference
105
1 reference
5
1 reference
908-919
1 reference